U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2004
210
Substance Class Protein
Created
by admin
on Sat Dec 16 17:50:25 GMT 2023
Edited
by admin
on Sat Dec 16 17:50:25 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
2S9ZZM9Q9V
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED
Preferred Name English
BEVACIZUMAB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
bevacizumab [INN]
Common Name English
BEVACIZUMAB [MART.]
Common Name English
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL RHUMAB-VEGF .GAMMA.-CHAIN ANTI-HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL RHUMAB-VEGF LIGHT CHAIN, DIMER
Common Name English
12-IGG1
Code English
RHUMAB-
Code English
BEVACIZUMAB [EMA EPAR]
Common Name English
BEVACIZUMAB [VANDF]
Common Name English
Bevacizumab [WHO-DD]
Common Name English
BEVACIZUMAB [MI]
Common Name English
BEVACIZUMAB [PURPLE BOOK CDER]
Common Name English
BEVACIZUMAB [JAN]
Common Name English
PF-06439535 [WHO-DD]
Common Name English
BEVACIZUMAB [USAN]
Common Name English
USP MAB 002, MONOCLONAL IGG1 [USP-RS]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 317810
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 222906
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 512215
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 505115
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 291709
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
LIVERTOX NBK548877
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
NDF-RT N0000178291
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
WHO-ATC L01XC07
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
NDF-RT N0000178292
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
EMA ASSESSMENT REPORTS AVASTIN (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 294409
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
WHO-VATC QL01XC07
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 318010
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 193704
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
EMA ASSESSMENT REPORTS AVASTIN (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
EMA ASSESSMENT REPORTS AVASTIN (AUTHORIZED: CARCINOMA, RENAL CELL)
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 317510
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
NCI_THESAURUS C2496
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
NDF-RT N0000193543
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 216405
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 619317
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
NDF-RT N0000020007
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
FDA ORPHAN DRUG 172903
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
EU-Orphan Drug EU/3/14/1390
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
Code System Code Type Description
RXCUI
253337
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY RxNorm
LACTMED
Bevacizumab
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
CAS
216974-75-3
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
INN
8017
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
DAILYMED
2S9ZZM9Q9V
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
MERCK INDEX
m2464
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
BEVACIZUMAB
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
FDA UNII
2S9ZZM9Q9V
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
RXCUI
2268037
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
ALTERNATIVE
NCI_THESAURUS
C2039
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
DRUG BANK
DB00112
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
SMS_ID
100000089535
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
RXCUI
2046138
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
ALTERNATIVE
EVMPD
SUB16402MIG
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
MESH
C469428
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
DRUG CENTRAL
4956
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201583
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
RS_ITEM_NUM
1445547
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
IUPHAR
6771
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
HSDB
8080
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
USAN
KK-78
Created by admin on Sat Dec 16 17:50:29 GMT 2023 , Edited by admin on Sat Dec 16 17:50:29 GMT 2023
PRIMARY
Related Record Type Details
Bevacizumab-ADCD
BIOSIMILAR -> PARENT
BEVACIZUMAB-AWWB
BIOSIMILAR -> PARENT
Q-1101
BIOSIMILAR -> PARENT
Bevacizumab-TNJN
BIOSIMILAR -> PARENT
Q-1101
TARGET -> ACTIVATOR
BEVACIZUMAB BIOSIMILAR (GP-2019)
SUB_CONCEPT->SUBSTANCE
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
BS-503
BIOSIMILAR -> PARENT
BI-695502
SUB_CONCEPT->SUBSTANCE
BEVACIZUMAB BIOSIMILAR (GP-2019)
BIOSIMILAR -> PARENT
HLX-04
SUB_CONCEPT->SUBSTANCE
HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A
TARGET -> INHIBITOR
BEVACIZUMAB-MALY
SUB_CONCEPT->SUBSTANCE
BEVACIZUMAB BETA
SUB_CONCEPT->SUBSTANCE
BEVACIZUMAB-AWWB
SUB_CONCEPT->SUBSTANCE
BS-503
SUB_CONCEPT->SUBSTANCE
BEVACIZUMAB (AVASTIN)
SUB_CONCEPT->SUBSTANCE
Bevacizumab-TNJN
SUB_CONCEPT->SUBSTANCE
Q-1101
SUB_CONCEPT->SUBSTANCE
IBI-305
BIOSIMILAR -> PARENT
LY-01008
BIOSIMILAR -> PARENT
BEVACIZUMAB-BVZR
SUB_CONCEPT->SUBSTANCE
FKB-238
SUB_CONCEPT->SUBSTANCE
Bevacizumab-ADCD
SUB_CONCEPT->SUBSTANCE
BEVACIZUMAB-BVZR
BIOSIMILAR -> PARENT
BEVACIZUMAB
SUB_CONCEPT->SUBSTANCE
LY-01008
SUB_CONCEPT->SUBSTANCE
BI-695502
BIOSIMILAR -> PARENT
IBI-305
SUB_CONCEPT->SUBSTANCE
HLX-04
BIOSIMILAR -> PARENT
Related Record Type Details
BEVACIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966